This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
Dashboard: Filter Bricks
Main page content
The Advisory outlines the principles and components of low barrier care, and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.
This report provides key findings from the 2022 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment among the noninstitutionalized U.S. population aged 12 or older. Estimates are presented by age group and by race/ethnicity for selected measures.
Mental Health Client-Level Data (MH-CLD) 2021: Data on Clients Receiving Mental Health Treatment Services Through State Mental Health Agencies annual report presents the total number of clients receiving mental health treatment services in 2021 by demographics, National Outcome Measures (NOMs), and the top five mental health diagnoses for children (ages 0-17) and adults (ages 18 and older) by geographic distribution.
This document updates SAMHSA’s 2018 document and outlines best practices for the implementation and operation of recovery housing. These best practices are intended to serve as a tool for states, governing bodies, providers, recovery house operators, and other interested stakeholders to improve the health of their citizens, reduce incidence of overdose, and promote recovery housing as a key support strategy in achieving and sustaining recovery.
The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.
This advisory discusses the epidemiology of the mental health symptoms and conditions of Long COVID, provides evidence-based resources for the treatment of those conditions, and offers possible resources.
An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.
Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.
Displaying 1 - 10 out of 78